These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7662605)

  • 1. Evaluation of neopterin as a marker for restenosis following percutaneous transluminal coronary angioplasty.
    Eber B; Schumacher M; Tatzber F; Kaufmann P; Luha O; Esterbauer H; Gasser R; Klein W
    Cardiovasc Drugs Ther; 1995 Apr; 9(2):361-2. PubMed ID: 7662605
    [No Abstract]   [Full Text] [Related]  

  • 2. Fibrinogen values in patients with and without restenosis following percutaneous transluminal coronary angiography.
    Schumacher M; Eber B; Tiran A; Toplak H; Luha O; Gasser R; Klein W
    Cardiology; 1992; 80(5-6):345-8. PubMed ID: 1451121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
    Hermans WR; Foley DP; Rensing BJ; Serruys PW
    Am Heart J; 1994 Mar; 127(3):483-94. PubMed ID: 8122593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restenosis after percutaneous transluminal coronary angioplasty.
    Pedersen HK; Vatne K; Simonsen S
    Acta Radiol; 1992 Mar; 33(2):149-51. PubMed ID: 1562409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: a prospective study.
    Miner SE; Hegele RA; Sparkes J; Teitel JM; Bowman KA; Connelly PW; Banijamali H; Lau HK; Chisholm RJ; Babaei S; Strauss BH
    Am Heart J; 2000 Aug; 140(2):272-8. PubMed ID: 10925342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restenosis after coronary angioplasty for rapidly progressive coronary stenosis.
    Bauters C; Passart F; Lablanche JM; McFadden EP; Hamon M; Bertrand ME
    Eur Heart J; 1996 Nov; 17(11):1671-7. PubMed ID: 8922915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipids and fatty acids and their relationship to restenosis.
    Foley JB; Younger K; Foley D; Kinsella A; Molloy M; Crean PA; Gearty G; Gibney M; Walsh MJ
    Cathet Cardiovasc Diagn; 1992 Jan; 25(1):25-30. PubMed ID: 1555223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine lipid profile in patients with and without restenosis after percutaneous transluminal coronary angioplasty.
    Schumacher M; Eber B; Toplak H; Klein W
    Am J Cardiol; 1992 Dec; 70(20):1640. PubMed ID: 1466350
    [No Abstract]   [Full Text] [Related]  

  • 9. Restenosis rate after multiple percutaneous transluminal coronary angioplasty procedures at the same site. A quantitative angiographic study in consecutive patients undergoing a third angioplasty procedure for a second restenosis.
    Bauters C; Mc Fadden EP; Lablanche JM; Quandalle P; Bertrand ME
    Circulation; 1993 Sep; 88(3):969-74. PubMed ID: 8353924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty.
    Horie H; Takahashi M; Izumi M; Takaoka A; Fujita T; Sakamoto T; Kito O; Okamura H; Kinoshita M
    Circulation; 1997 Jul; 96(1):166-73. PubMed ID: 9236431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum lipids and restenosis after successful percutaneous transluminal coronary angioplasty. Ichilov Magnesium Study Group.
    Roth A; Eshchar Y; Keren G; Sheps D; Kerbal S; Laniado S; Miller HI; Rubinstein A
    Am J Cardiol; 1994 Jun; 73(16):1154-8. PubMed ID: 8203331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in restenosis propensity of devices for transluminal coronary intervention. A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. CARPORT, MERCATOR, MARCATOR, PARK, and BENESTENT Trial Groups.
    Foley DP; Melkert R; Umans VA; de Jaegere PP; Strikwerda S; de Feyter PJ; Serruys PW
    Eur Heart J; 1995 Oct; 16(10):1331-46. PubMed ID: 8746901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of serum lipid concentrations on restenosis after successful de novo percutaneous transluminal coronary angioplasty in patients with total cholesterol 160 to 240 mg/dl and triglycerides < 350 mg/dl.
    Dzavik V; Teo KK; Yokoyama S; Modi R; Dinwoodie A; Burton JR; Tymchak WJ; Montague TJ
    Am J Cardiol; 1995 May; 75(14):936-8. PubMed ID: 7733005
    [No Abstract]   [Full Text] [Related]  

  • 14. Coronary angioplasty induces a systemic inflammatory response.
    Azar RR; McKay RG; Kiernan FJ; Seecharran B; Feng YJ; Fram DB; Wu AH; Waters DD
    Am J Cardiol; 1997 Dec; 80(11):1476-8. PubMed ID: 9399726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
    Yokoi H; Daida H; Kuwabara Y; Nishikawa H; Takatsu F; Tomihara H; Nakata Y; Kutsumi Y; Ohshima S; Nishiyama S; Seki A; Kato K; Nishimura S; Kanoh T; Yamaguchi H
    J Am Coll Cardiol; 1997 Oct; 30(4):855-62. PubMed ID: 9316509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
    Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
    J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group.
    Daida H; Lee YJ; Yokoi H; Kanoh T; Ishiwata S; Kato K; Nishikawa H; Takatsu F; Kato H; Kutsumi Y
    Am J Cardiol; 1994 Jun; 73(15):1037-40. PubMed ID: 8198026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restenosis after transluminal coronary angioplasty: a risk factor analysis.
    Gürlek A; Dağalp Z; Oral D; Omürlü K; Erol C; Akyol T; Tutar E
    J Cardiovasc Risk; 1995 Feb; 2(1):51-5. PubMed ID: 7606641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recanalization of chronic coronary artery occlusions using laser followed by balloon angioplasty.
    Schofer J; Kresser J; Rau T; Kunze KP; Kühn CR; Mathey DG
    Am J Cardiol; 1996 Oct; 78(7):836-8. PubMed ID: 8857495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA).
    DeMaio SJ; King SB; Lembo NJ; Roubin GS; Hearn JA; Bhagavan HN; Sgoutas DS
    J Am Coll Nutr; 1992 Feb; 11(1):68-73. PubMed ID: 1541798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.